The Application of Nuclear Medicine

Currently, the practice of nuclear medicine in modern countries comprises a large number of procedures. It is applied to study function of organs/body systems, to visualize, to characterize, and to quantify the functional state of lesions and for targeted radionuclide therapy. This overview presents all kinds of application in nuclear medicine services. Instrumentation and radioactive/radiolabeled substances are the basic components for application. Biotechnology contributes to the development and production of biomolecules used in radiopharmaceuticals. As a diagnostic modality, imaging depicts radioactivity distribution as a function of time. Hybrid imaging provides more precise localization and definition of le-sions as well as molecular imaging cross validation. Counting tests study invivo<br />organ functions externally or assess analytes in the biologic samples. Radiopharmaceutical therapy can be applied directly into the lesion or targeted systemically. Nanotechnology facilitates targeting and opens the development of bimodal techniques. In addition, neutron application contributes to the advancement of nuclear medicine services, such as neutron activation analysis, neutron teletherapy and neutron capture therapy.

Download Full-text

Bifunctional Chelators for Radiorhenium: Past, Present and Future Outlook

RSC Medicinal Chemistry ◽

10.1039/d1md00364j ◽

2022 ◽

Author(s):

Diana Melis ◽

Andrew Burgoyne ◽

Maarten Ooms ◽

Gilles Gasser

Keyword(s):

Nuclear Medicine ◽

Cancer Treatment ◽

Radionuclide Therapy ◽

Targeted Radionuclide Therapy ◽

Future Outlook ◽

Bifunctional Chelators ◽

Normal Tissues

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that provides a personalised approach to cancer treatment while limiting toxicity to normal tissues. It involves the radiolabelling of...

Download Full-text

Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging

Journal of Nuclear Medicine ◽

10.2967/jnumed.113.135178 ◽

2014 ◽

Vol 55 (2) ◽

pp. 337-348 ◽

Cited By ~ 13

Author(s):

F. Fahey ◽

K. Zukotynski ◽

J. Capala ◽

N. Knight ◽

Keyword(s):

Nuclear Medicine ◽

Molecular Imaging ◽

National Cancer Institute ◽

Radionuclide Therapy ◽

Targeted Radionuclide Therapy ◽

Joint Workshop

Download Full-text

Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

British Journal of Radiology ◽

10.1259/bjr.20190117 ◽

2019 ◽

Vol 92 (1100) ◽

pp. 20190117 ◽

Cited By ~ 1

Author(s):

Nadia Falzone ◽

Rebecca Gregory ◽

Matthew Aldridge ◽

Samantha YA Terry ◽

Glenn Flux

Keyword(s):

Clinical Trials ◽

Nuclear Medicine ◽

Radionuclide Therapy ◽

Targeted Radionuclide Therapy ◽

Molecular Radiotherapy ◽

Challenges And Opportunities ◽

The Uk

It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI–CTRad (Clinical Trials in Molecular Radiotherapy–Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI–CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.

Download Full-text